EA7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France; ER045, PRASE, Biology Department, Faculty of Sciences, Lebanese University, Beirut, Lebanon.
EA7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France.
J Mol Cell Cardiol. 2019 Apr;129:2-12. doi: 10.1016/j.yjmcc.2019.01.021. Epub 2019 Feb 12.
Calcific aortic valve disease (CAVD) is the most common heart valve disease in western countries. It has been reported that activation of the calcium-sensing receptor(CaSR) expressed by vascular smooth muscle cells prevents vascular calcification. However, to date, the CaSR's expression and function in cardiac valves have not been studied. The present study sought to evaluate the presence of the CaSR within human valvular interstitial cells (hVICs), assess the CaSR's functionality, and ascertain its involvement in hVIC calcification.
Data from Western blot, flow cytometry and immunocytochemistry experiments demonstrated that primary hVICs express the CaSR. The receptor was functional, since the incubation of hVICs with the calcimimetic R-568 significantly increased Ca-induced ERK1/2 phosphorylation, and exposure to the calcilytic NPS2143 reduced ERK1/2 activation. A reduction in endogenous CaSR expression by hVICs (using siRNA) was associated with significantly lower levels of Ca-induced mineralization (quantified using Alizarin Red staining). Similar data were obtained after the pharmacological inhibition of CaSR activity by the calcilytic NPS2143. In contrast, overexpression of a functional CaSR amplified Ca-induced calcification. Pharmacological activation of the CaSR with the calcimimetic R-568 showed similar effects. CaSR's procalcific properties are associated with increased osteogenic transition (as characterized by elevated mRNA expression of bone morphogenetic protein 2 and osterix), and reduced the expression of the calcification inhibitor osteopontin. Histological analysis of 12 human aortic tricuspid valves showed that CaSR expression was greater in calcified areas than in non-calcified areas. These data were confirmed by Western blots.
To the best of our knowledge, this study is the first to have demonstrated that hVICs express a functional CaSR. Taken as a whole, our data suggest that activation of the CaSR expressed by hVICs might be a key promoter of CAVD progression.
钙化性主动脉瓣疾病(CAVD)是西方国家最常见的心脏瓣膜病。据报道,血管平滑肌细胞中钙敏感受体(CaSR)的激活可防止血管钙化。然而,迄今为止,心脏瓣膜中 CaSR 的表达和功能尚未得到研究。本研究旨在评估人心脏瓣膜间质细胞(hVICs)中 CaSR 的存在,评估其功能,并确定其在 hVIC 钙化中的作用。
Western blot、流式细胞术和免疫细胞化学实验的数据表明,原代 hVICs 表达 CaSR。该受体具有功能,因为 hVICs 孵育在钙敏感受体激动剂 R-568 中可显著增加钙诱导的 ERK1/2 磷酸化,而暴露于钙敏感受体拮抗剂 NPS2143 可降低 ERK1/2 的激活。hVICs 中内源性 CaSR 表达的减少(使用 siRNA)与钙诱导的矿化水平明显降低有关(通过茜素红染色进行定量)。在用钙敏感受体拮抗剂 NPS2143 抑制 CaSR 活性后,获得了类似的数据。相反,功能 CaSR 的过表达放大了钙诱导的钙化。用钙敏感受体激动剂 R-568 激活 CaSR 显示出相似的效果。CaSR 的促钙化特性与成骨转化增加(特征为骨形态发生蛋白 2 和osterix 的 mRNA 表达升高)和钙化抑制剂骨桥蛋白的表达降低有关。对 12 个人主动脉三尖瓣的组织学分析表明,在钙化区 CaSR 的表达高于非钙化区。Western blot 验证了这些数据。
据我们所知,这项研究首次证明 hVICs 表达功能性 CaSR。总的来说,我们的数据表明,hVICs 表达的 CaSR 的激活可能是 CAVD 进展的关键促进因素。